
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL Inc has experienced a substantial share appreciation of nearly 90% in the past month, driven by optimistic developments from the PATHFINDER 2 ESMO data readout and the potential positive outcome of the NHS Galleri trial. The company’s Total Addressable Market (TAM) analysis indicates a significant revenue opportunity, estimated at approximately $3.7 billion in the UK by 2026, growing to $4.0 billion by 2035, further supported by partnerships that enhance access to this market. Additionally, GRAIL's pending $400 million infusion into its balance sheet bolsters its financial position, despite lingering uncertainties surrounding Medicare reimbursement and regulatory approvals.
Bears say
GRAIL Inc. has consistently reported significant net losses since its inception and projects ongoing financial deficits as it continues to pursue regulatory approvals and expand its operations. Key risks impacting the company's outlook include potential delays in legislative support for reimbursements of its mult-cancer early detection (MCED) tests, adoption challenges for this novel technology, and competitive pressure from larger diagnostic firms with established infrastructure. Additionally, rising selling, general, and administrative expenses related to the growth of Galleri volumes and uncertainty regarding timely clinical study results further complicate GRAIL's commercial viability and financing prospects.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares